Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells.
Zhang N, Nan A, Chen L, Li X, Jia Y, Qiu M, Dai X, Zhou H, Zhu J, Zhang H, Jiang Y.
Mol Cancer. 2020 Jun 3;19(1):101. doi: 10.1186/s12943-020-01221-6.
Outcome of bronchial carcinoma in situ.
Venmans BJ, van Boxem TJ, Smit EF, Postmus PE, Sutedja TG.
Chest. 2000 Jun;117(6):1572-6. doi: 10.1378/chest.117.6.1572.
Outcomes after sublobar resection versus lobectomy in non-small cell carcinoma in situ.
Perez Holguin RA, Olecki EJ, Wong WG, Stahl KA, Go PH, Taylor MD, Reed MF, Shen C.
J Thorac Cardiovasc Surg. 2023 Mar;165(3):853-861.e3. doi: 10.1016/j.jtcvs.2022.05.032. Epub 2022 Jun 1.
Chinese expert consensus on the diagnosis and treatment of HER2-altered non-small cell lung cancer.
Zhang S, Wang W, Xu C, Zhang Y, Cai X, Wang Q, Song Z, Li Z, Yu J, Zhong W, Wang Z, Liu J, Liu A, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Lin G, Huang L, Yuan J, Jiang Z, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Zhou J, Zhu Z, Pan W, Dong X, Pang F, Wang K, Yao C, Lin G, Li S, Yang Z, Luo J, Jia H, Nie X, Wang L, Zhu Y, Hu X, Xie Y, Lin X, Cai J, Xia Y, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Kang J, Zhang J, Zhang C, Gao W, Huang J, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Wan B, Lv D, Yu G, Shi L, Xia Y, Gao F, Zhang X, Xu T, Zhou W, Wang H, Liu Z, Yang N, Wu L, Wang Q, Wang G, Hong Z, Wang J, Fang M, Fang Y, Zhang Y, Song Y, Ma S, Fang W, Lu Y.
Thorac Cancer. 2023 Jan;14(1):91-104. doi: 10.1111/1759-7714.14743. Epub 2022 Nov 28.
LncRNA PKMYT1AR promotes cancer stem cell maintenance in non-small cell lung cancer via activating Wnt signaling pathway.
He Y, Jiang X, Duan L, Xiong Q, Yuan Y, Liu P, Jiang L, Shen Q, Zhao S, Yang C, Chen Y.
Mol Cancer. 2021 Dec 2;20(1):156. doi: 10.1186/s12943-021-01469-6.
Focus of bronchial carcinoma in situ eradicated by endobronchial biopsy.
Infeld M, Gerblich A, Subramanyan S, Whitlesey D.
Chest. 1988 Nov;94(5):1107-9. doi: 10.1378/chest.94.5.1107.
Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
Luk PP, Selinger CI, Mahar A, Cooper WA.
Arch Pathol Lab Med. 2018 Aug;142(8):922-928. doi: 10.5858/arpa.2017-0502-RA. Epub 2018 Jun 14.
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH.
Lung Cancer. 2021 Jul;157:17-20. doi: 10.1016/j.lungcan.2021.05.028. Epub 2021 May 26.
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.
Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K.
J Clin Oncol. 2018 May 10;36(14):1405-1411. doi: 10.1200/JCO.2017.75.5587. Epub 2018 Mar 29.
Different In Situ Immune Patterns between Primary Tumor and Lymph Node in Non-Small-Cell Lung Cancer: Potential Impact on Neoadjuvant Immunotherapy.
Ye ZH, Long H, Zhao ZR.
J Immunol Res. 2022 Apr 28;2022:8513747. doi: 10.1155/2022/8513747. eCollection 2022.
